Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0D0QA
|
|||
| Former ID |
DCL000476
|
|||
| Drug Name |
AZD6482
|
|||
| Synonyms |
AZD6482; 1173900-33-8; AZD 6482; (R)-2-(1-(7-methyl-2-morpholino-4-oxo-4H-pyrido[1,2-a]pyrimidin-9-yl)ethylamino)benzoic acid; 2-[[(1R)-1-[7-Methyl-2-(4-morpholinyl)-4-oxo-4H-pyrido[1,2-a]pyrimidin-9-yl]ethyl]amino]benzoic acid; AZD-6482; CHEMBL2165191; UNII-78G6MP5PZ5; 78G6MP5PZ5; 2-({(1R)-1-[7-Methyl-2-(morpholin-4-yl)-4-oxo-4H-pyrido[1,2-a]pyrimidin-9-yl]ethyl}amino)benzoic acid; 2-{[(1R)-1-[7-methyl-2-(morpholin-4-yl)-4-oxopyrido[1,2-a]pyrimidin-9-yl]ethyl]amino}benzoic acid
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Thrombosis [ICD-11: DB61-GB90; ICD-10: I80-I82] | Terminated | [1], [2] | |
| Company |
AstraZeneca
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C22H24N4O4
|
|||
| Canonical SMILES |
CC1=CN2C(=O)C=C(N=C2C(=C1)C(C)NC3=CC=CC=C3C(=O)O)N4CCOCC4
|
|||
| InChI |
1S/C22H24N4O4/c1-14-11-17(15(2)23-18-6-4-3-5-16(18)22(28)29)21-24-19(12-20(27)26(21)13-14)25-7-9-30-10-8-25/h3-6,11-13,15,23H,7-10H2,1-2H3,(H,28,29)/t15-/m1/s1
|
|||
| InChIKey |
IRTDIKMSKMREGO-OAHLLOKOSA-N
|
|||
| CAS Number |
CAS 1173900-33-8
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
85093417, 89932412, 104253172, 124757268, 125164072, 131480885, 135727438, 136367432, 137275998, 137725745, 143499711, 144115658, 152074433, 152237519, 152258189, 152344029, 160647025, 162011836, 162037612, 163320808, 163344845, 165238060, 170498576, 172657672, 174525864, 177748950, 184816359, 188899561, 202818127, 223390326, 223605958, 223705060, 224296688, 227986843, 248897842, 249565739, 249814471, 251962982, 252158404, 252443761, 252450556, 252470606, 252821095
|
|||
| ChEBI ID |
CHEBI:91359
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8059). | |||
| REF 2 | Human target validation of phosphoinositide 3-kinase (PI3K)beta: effects on platelets and insulin sensitivity, using AZD6482 a novel PI3Kbeta inhibitor. J Thromb Haemost. 2012 Oct;10(10):2127-36. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.